PIS
VRTX icon

POM Investment Strategies’s Vertex Pharmaceuticals VRTX Stock Holding History

POM Investment Strategies’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10
Closed -$4.46K – 468
2026
Q1 		$4.46K Buy
+10
New +$4.66K 0.01% 278
2025
Q2 		– Sell
-8
Closed -$3.88K – 229
2025
Q1 		$3.88K Hold
8
– – ﹤0.01% 123
2024
Q4 		$3.22K Hold
8
– – ﹤0.01% 245
2024
Q3 		$3.72K Hold
8
– – ﹤0.01% 189
2024
Q2 		$3.75K Hold
8
– – ﹤0.01% 241
2024
Q1 		$3.34K Hold
8
– – ﹤0.01% 156
2023
Q4 		$3.25K Buy
+8
New +$2.96K ﹤0.01% 144

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

POM Investment Strategies's VRTX Position: Q2 2026 in Review

POM Investment Strategies sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 10 shares — an estimated $4.46K sold.

POM Investment Strategies first reported a position in VRTX in Q4 2023 and held it in 7 quarters. The position peaked at $4.46K in Q1 2026. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • POM Investment Strategies reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • POM Investment Strategies sold 10 Vertex Pharmaceuticals shares in Q2 2026, an estimated $4.46K.
  • POM Investment Strategies first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 7 quarters.
  • POM Investment Strategies's Vertex Pharmaceuticals position peaked at $4.46K in Q1 2026.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on POM Investment Strategies's 13F filing for Q2 2026, filed 31 Jul 2026.